VisualMED Clinical Solutions Corp. (OTCPK:VMCS) entered into an agreement to acquire Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. from Rennova Health, Inc. on May 12, 2021. Once the agreement has closed VisualMed intends to complete a name change and these entities will operate as wholly owned subsidiaries of VisualMED. As part of the agreement VisualMED is required to complete any outstanding filings necessary to be fully compliant with OTC reporting requirements before closing and the closing is subject to a number of customary conditions for a transaction of this nature and is intended to happen on or before May 31, 2020.

VisualMED Clinical Solutions Corp. (OTCPK:VMCS) completed the acquisition of Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. from Rennova Health, Inc. on June 25, 2021. As of July 1, 2021, VisualMED Clinical Solutions Corp. issued 0.014 million shares of Series B Non-Voting Convertible Preferred Stock. The number of shares of Series B Preferred Stock will be subject to a post-closing adjustment which resulted in 950 additional shares of Series B Preferred Stock due Rennova which were issued in September 2021. For the year ended December 31, 2020, Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. reported combined net revenues of $528,624, net loss of $606,451, and total assets of $185,059. The transaction was subject to regulatory and shareholder approvals, execution of consulting agreement, and financial audit of the targets. J. Thomas Cookson of Shutts & Bowen LLP acted as legal advisor to Rennova Health, Inc.